{5-(4-(N,N-dimethylamino)phenyl)-2-((4-pyridylmethyl)amino)pyrimidin-4-yl}[1-benzyl(4-piperidyl)]amine | 637356-66-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: {5-(4-(N,N-dimethylamino)phenyl)-2-((4-pyridylmethyl)amino)pyrimidin-4-yl}[1-benzyl(4-piperidyl)]amine
• 英文别名: {5-(4-(N,N-Dimethylamino)phenyl)-2-[(4-pyridylmethyl)amino)pyrimidin-4-yl}[1-benzyl(4-piperidyl)]amine；4-N-(1-benzylpiperidin-4-yl)-5-[4-(dimethylamino)phenyl]-2-N-(pyridin-4-ylmethyl)pyrimidine-2,4-diamine
• CAS: 637356-66-2
• 化学式: C₃₀H₃₅N₇
• 分子量: 493.655
• InChiKey: GAHAAQDVPZTLGF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  69.2
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  {5-bromo-2-[(4-pyridylmethyl) amino]pyrimidin-4-yl}[1-benzyl(4-piperidyl)]amine 、 4-二甲基氨基苯硼酸 、 [1-Benzyl(4-piperidyl)]{2-[(2-pyridylmethyl)amino]-5-(3-thienyl)pyrimidin-4-yl}amine 生成 {5-(4-(N,N-dimethylamino)phenyl)-2-((4-pyridylmethyl)amino)pyrimidin-4-yl}[1-benzyl(4-piperidyl)]amine
  参考文献：
  名称：

  Substituted diaminopyrimidines

  摘要：

  本发明涉及取代二氨基嘧啶化合物，这些化合物是治疗与蛋白激酶Cθ（PKCθ）抑制剂常用治疗的疾病和障碍相关的有效治疗化合物。

  公开号：

  US20050222186A1

文献信息

• [EN] SUBSTITUTED DIAMINOPYRIMIDINES<br/>[FR] DIAMINOPYRIMIDINES SUBSTITUES
  申请人：ALTANA PHARMA AG

  公开号：WO2003106451A1

  公开（公告）日：2003-12-24

  The invention relates to substituted diaminopyrimidine compounds, which are effective therapeutic compounds for treating diseases and disorders associated with those commonly treated by Protein Kinase C theta (PKCθ) inhibitors.

  这项发明涉及替代二氨基嘧啶化合物，这些化合物是治疗与蛋白激酶Cθ（PKCθ）抑制剂通常治疗的疾病和疾病相关的有效治疗化合物。
• SUBSTITUTED DIAMINOPYRIMIDINES
  申请人：ALTANA Pharma AG

  公开号：EP1515964A1

  公开（公告）日：2005-03-23
• COMPOSITIONS FOR MODULATING CANCER STEM CELLS AND USES THEREFOR
  申请人：University of Canberra

  公开号：EP3185858A1

  公开（公告）日：2017-07-05
• Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
  申请人：Ward Keith W.

  公开号：US20090291073A1

  公开（公告）日：2009-11-26

  Compositions for treating or controlling: (i) an eye condition, disorder, or disease, or (ii) a degeneration of a component of an optic nerve system in a subject, comprise a PKC-θ inhibitor. The compositions can further include an anti-inflammatory or anti-glaucoma medicament. Such a condition or degeneration has an inflammatory component.
• Compositions for Modulating Cancer Stem Cells and Uses Therefor
  申请人：University of Canberra

  公开号：US20170266140A1

  公开（公告）日：2017-09-21

  Disclosed are compositions and methods for modulating cancer stem cells. More particularly, the present invention discloses the use of lysine demethylase (LSD) inhibitors and protein kinase C theta inhibitors (PKC-θ) for inhibiting the growth of LSD- and/or PKC-θ-overexpressing cells including cancer stem cells, for enhancing the biological effects of chemotherapeutic drugs or irradiation on cancer cells, for treating cancer, including non-metastatic and metastatic cancer and/or for preventing cancer recurrence.